Zhi Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhi Li has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
A-Mei Chen
Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
1 shared publication- Ailong Huang
Department of Infectious Diseases Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education) Institute for Viral Hepatitis The Second Affiliated Hospital Chongqing Medical University Chongqing China
1 shared publication - Chang Chen
College of Pharmacy, Chongqing Medical University , Chongqing
1 shared publication - Dongmei Gou
Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital
1 shared publication - Feng Liu
Department of Emergency, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication - Guo-Chao Zhong
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication
Latest Publications
- Open Access
- 3 July 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (13)
Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression
Deciphering the crosstalk between metabolic reprogramming and epigenetic regulation is a promising strategy for cancer therapy. In this study, we discovered that the gluconeogenic enzyme PCK1 fueled the generation of S-adenosylmethionine (SAM) through the serine synthesis pathway. The methyltransferase SUV39H1 catalyzed SAM, which served as a methyl donor to support H3K9me3 modification, leading to the suppression of the oncogene S100A11. Mechanistically, PCK1 deficiency–induced oncogenic activation of S100A11 was due to its interaction with AKT1, which upregulated PI3K/AKT signaling. Intriguingly, the progression of hepatocellular carcinoma (HCC) driven by PCK1 deficiency was suppressed by SAM supplement or S100A11 KO in vivo and in vitro. These findings reveal the availability of the key metabolite SAM as a bridge connecting the gluconeogenic enzyme PCK1 and H3K9 trimethylation in attenuating HCC progression, thus suggesting a potential therapeutic strategy against HCC.
- 3 July 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (13)
Open AccessGluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression
Deciphering the crosstalk between metabolic reprogramming and epigenetic regulation is a promising strategy for cancer therapy. In this study, we discovered that the gluconeogenic enzyme PCK1 fueled the generation of S-adenosylmethionine (SAM) through the serine synthesis pathway. The methyltransferase SUV39H1 catalyzed SAM, which served as a methyl donor to support H3K9me3 modification, leading to the suppression of the oncogene S100A11. Mechanistically, PCK1 deficiency–induced oncogenic activation of S100A11 was due to its interaction with AKT1, which upregulated PI3K/AKT signaling. Intriguingly, the progression of hepatocellular carcinoma (HCC) driven by PCK1 deficiency was suppressed by SAM supplement or S100A11 KO in vivo and in vitro. These findings reveal the availability of the key metabolite SAM as a bridge connecting the gluconeogenic enzyme PCK1 and H3K9 trimethylation in attenuating HCC progression, thus suggesting a potential therapeutic strategy against HCC.
- 1 November 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (11) , 5595-5604
Type 2 diabetes prevention diet and the risk of pancreatic cancer: A large prospective multicenter study
- 1 November 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (11) , 5595-5604
Type 2 diabetes prevention diet and the risk of pancreatic cancer: A large prospective multicenter study